keyword
MENU ▼
Read by QxMD icon Read
search

Intermediate uveitis

keyword
https://www.readbyqxmd.com/read/28426849/effect-of-adalimumab-on-visual-functioning-in-patients-with-noninfectious-intermediate-uveitis-posterior-uveitis-and-panuveitis-in-the-visual-1-and-visual-2-trials
#1
John Sheppard, Avani Joshi, Keith A Betts, Stacie Hudgens, Samir Tari, Naijun Chen, Martha Skup, Andrew D Dick
Importance: Adalimumab was recently approved for the treatment of noninfectious intermediate uveitis, posterior uveitis, and panuveitis. Objective: To assess the effect of adalimumab on the visual functioning and quality of life in patients with corticosteroid-dependent noninfectious intermediate uveitis, posterior uveitis, and panuveitis. Design: A post hoc analysis of clinical trials of adults with active (VISUAL-1) and inactive (VISUAL-2) noninfectious intermediate uveitis, posterior uveitis, and panuveitis was conducted in the United States, Canada, Europe, Israel, Australia, Latin America, and Japan...
April 20, 2017: JAMA Ophthalmology
https://www.readbyqxmd.com/read/28419401/unilateral-pigmented-paravenous-retinochoroidal-atrophy-associated-with-presumed-ocular-tuberculosis
#2
Guillermo Fernandez-Sanz, Ester Carreño, Sonia Mall, Magella M Neveu, Graham E Holder, Dhanes Thomas
This report describes a case of unilateral pigmented paravenous retinochoroidal atrophy (PPRCA) in a patient with low-grade unilateral intermediate uveitis. A 31-year-old woman, previously diagnosed with intermediate uveitis in the right eye (OD) presented to the clinic. Best-corrected visual acuity was 20/20 OD. Fundus examination, fluorescein angiography, autofluorescence, and optical coherence tomography OD were in keeping with a phenotypic diagnosis of PPRCA. Electrophysiology showed severe photoreceptor dysfunction of both the rod and the cone systems OD...
April 1, 2017: Ophthalmic Surgery, Lasers & Imaging Retina
https://www.readbyqxmd.com/read/28414043/quality-of-life-outcomes-from-a-randomized-clinical-trial-comparing-antimetabolites-for-intermediate-posterior-and-panuveitis
#3
Katherine M Niemeyer, John A Gonzales, Sivakumar R Rathinam, Manohar Babu, Radhika Thundikandy, Anuradha Kanakath, Travis C Porco, Erica N Browne, Maya M Rao, Nisha R Acharya
PURPOSE: To evaluate the changes in quality of life in noninfectious uveitis patients treated with two of the most commonly prescribed antimetabolite treatments. DESIGN: Secondary analysis of a multicenter, block-randomized, clinical trial (ClinicalTrials.gov NCT01232920). METHODS: Eighty patients at Aravind Eye Hospitals in Madurai and Coimbatore, India, with noninfectious intermediate, posterior, or panuveitis were randomized to receive oral methotrexate, 25 mg weekly, or oral mycophenolate mofetil, 1 g twice daily, and were followed up monthly for 6 months...
April 13, 2017: American Journal of Ophthalmology
https://www.readbyqxmd.com/read/28408754/lack-of-association-of-c3-gene-with-uveitis-additional-insights-into-the-genetic-profile-of-uveitis-regarding-complement-pathway-genes
#4
Ming Ming Yang, Jun Wang, Li Dong, De Ju Kong, Yan Teng, Ping Liu, Jiao Jie Fan, Xu Hui Yu
Uveitis is a devastating ocular disease that causes blindness. Our previous studies have achieved great advancements in depicting the genetic profiles of uveitis regarding complement pathway genes. This study aimed to provide additional insights into this interest by testing the "central" factor of the complement system, C3 gene variants, in two uveitis entities. Eight haplotype-tagging SNPs of C3 gene were genotyped in 141 anterior uveitis (AU), 158 non-infectious intermediate and posterior uveitis (NIPU) and 293 controls...
April 13, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28389773/analysis-of-clinical-features-and-visual-outcomes-of-pars-planitis
#5
Nilufer Berker, Emine Sen, Ufuk Elgin, Cemile Ucgul Atilgan, Erdem Dursun, Pelin Yilmazbas
PURPOSE: To evaluate the demographic characteristics, clinical features, treatment and outcomes of patients with pars planitis in a tertiary referral center in Turkey. METHODS: Medical records of patients with pars planitis were retrospectively reviewed. The data including demographic and ocular features and treatment outcomes were recorded. The distribution of clinical findings and complications were evaluated according to age and gender groups. The changes in final BCVA compared to the initial BCVA were noted...
April 7, 2017: International Ophthalmology
https://www.readbyqxmd.com/read/28366648/randomized-control-trial-evaluating-a-standardized-strategy-for-uveitis-etiological-diagnosis-ulisse
#6
Audrey de Parisot, Laurent Kodjikian, Marie-Hélène Errera, Neila Sedira, Emmanuel Heron, Laurent Pérard, Pierre-Loïc Cornut, Christelle Schneider, Sophie Rivière, Priscille Ollé, Grégory Pugnet, Pascal Cathébras, Pierre Manoli, Bahram Bodaghi, David Saadoun, Stéphanie Baillif, Nathalie Tieulie, Marc Andre, Frédéric Chiambaretta, Nicolas Bonin, Philip Bielefeld, Alain Bron, Frédéric Mouriaux, Boris Bienvenu, Stéphanie Vicente, Sylvie Bin, Christiane Broussolle, Evelyne Decullier, Pascal Sève
PURPOSE: To prospectively assess the efficiency of a standardized diagnostic approach, compared to an open strategy, for the etiological diagnosis of uveitis. DESIGN: Non-inferiority, prospective, multicenter, clustered randomized control trial. METHODS: Consecutive patients with uveitis, who visited one of the participating Departments of Ophthalmology, were included. In the standardized group, all patients had a minimal work-up regardless of the type of uveitis (complete blood count, erythrocyte sedimentation rate, C-reactive protein, tuberculin skin test, syphilis serology and chest X ray) followed by more complex investigations according to ophthalmological findings...
March 30, 2017: American Journal of Ophthalmology
https://www.readbyqxmd.com/read/28353369/cystoid-macular-edema-in-retinitis-pigmentosa-with-intermediate-uveitis-responded-well-to-oral-and-posterior-subtenon-steroid
#7
Koushik Tripathy
No abstract text is available yet for this article.
March 29, 2017: Seminars in Ophthalmology
https://www.readbyqxmd.com/read/28345572/late-dislocation-of-in-the-bag-intraocular-lenses-in-uveitic-eyes-an-analysis-of-management-and-complications
#8
Sudha K Ganesh, Parveen Sen, Hitesh R Sharma
AIM: An analysis of late in-the-bag dislocation of intraocular lenses (IOL), in uveitic eyes. SETTING: Referral uveitis clinic. DESIGN: Retrospective case series. MATERIALS AND METHODS: All case records of eyes with chronic uveitis that had phacoemulsification with IOL implantation, at a referral uveitis clinic between February 1997 and January 2015 were retrieved and analyzed. Only those eyes with no documented intraoperative complication and no predisposing risks to IOL dislocation, such as pseudoexfoliation, high myopia, trauma, and prior VR surgery were included in this study...
February 2017: Indian Journal of Ophthalmology
https://www.readbyqxmd.com/read/28337062/successful-treatment-of-beh%C3%A3-et-s-uveitis-with-tocilizumab
#9
F Alokaily, A Al Saati, A Jawad
A 33-year-old man with history of lymphoma was misdiagnosed as multiple sclerosis (MS) 18 months previously, developed intermediate uveitis, unresponsive to interferon, and corticosteroids. A diagnosis of Behçet's disease (BD) was made on the basis of recurrent orogenital ulceration, erythema nodosum, and a positive pathergy test. The patient was started on Tocilizumab and experienced an improvement in visual acuity and intraocular inflammation over the following 2 weeks. In patients with BD-related uveitis, Tocilizumab can be an effective alternative to anti-tumor necrosis factor alpha medications...
January 2017: Saudi Journal of Ophthalmology: Official Journal of the Saudi Ophthalmological Society
https://www.readbyqxmd.com/read/28329887/listeria-monocytogenes-endophthalmitis-after-intermediate-uveitis-and-ppv-for-retinal-detachment
#10
Betül Parlar, Andreas Zettl, Heinrich Gerding
No abstract text is available yet for this article.
March 22, 2017: Klinische Monatsblätter Für Augenheilkunde
https://www.readbyqxmd.com/read/28324879/quantitative-analysis-of-uveitis-macular-edema-in-multiple-sclerosis-patients-receiving-deep-posterior-sub-tenon-triamcinolone-acetonide-injection
#11
Svetlana Jovanović, Tatjana Šarenac Vulović, Filip Radotić, Zorica Tončić, Maja Živković, Nenad Petrović
AIM: We aimed to analyze the effects of adjunctive posterior sub-Tenon capsule triamcinolone acetonide injection in the treatment of intermediate uveitis macular edema in multiple sclerosis patients that could not be controlled by systemic corticosteroid medications and immunomodulators. METHODS: The study included 30 eyes of 25 patients with multiple sclerosis who received a posterior sub-Tenon injection of 40 mg/mL triamcinolone acetonide. Parameters monitored for therapy efficiency were best-corrected visual acuity, intraocular pressure, central foveal thickness (CFT), and fluorescein angiography (FA) scores...
March 22, 2017: Ophthalmic Research
https://www.readbyqxmd.com/read/28323505/pattern-of-uveitis-in-a-referral-hospital-in-bangladesh
#12
Zahedur Rahman, Ziaul Ahsan, Niaz Abdur Rahman, Parthopratim Dutta Majumder
PURPOSE: To report the pattern of uveitis in a tertiary eye care center in Bangladesh. METHODS: Retrospective analysis of all uveitis cases visiting uveitis clinic of Bangladesh Eye Hospital between January, 2009 and April, 2015. RESULTS: In total, 652 patients (mean age 32.3 years, female 47.8%) were included in the study. Uveitis was bilateral in 42.6% of cases. Anterior uveitis was the most common (39.2%) case, closely followed by intermediate uveitis (22...
March 21, 2017: Ocular Immunology and Inflammation
https://www.readbyqxmd.com/read/28318350/clinical-course-and-outcomes-of-pediatric-tubercular-uveitis-in-north-india
#13
Savleen Kaur, Kanika Aggarwal, Aniruddha Agarwal, Deepti Suri, Anju Gupta, Ramandeep Singh, Reema Bansal, Surjit Singh, Nirbhai Singh, Amod Gupta, Vishali Gupta
PURPOSE: To analyze the clinical features, course, management, and outcomes of tubercular (TB) uveitis in the pediatric population and assess the response to anti-tubercular therapy (ATT). METHODS: Hospital records of children (≤16 years) from a large tertiary-care institute between January 2001 and December 2015 were reviewed. RESULTS: A total of 32 children (mean age: 10.7 ± 4.27 years; range 2-16) were diagnosed with TB-associated uveitis...
March 20, 2017: Ocular Immunology and Inflammation
https://www.readbyqxmd.com/read/28257832/risk-factors-for-the-development-of-cataract-in-children-with-uveitis
#14
Tamar Blum-Hareuveni, Sophie Seguin-Greenstein, Michal Kramer, Guy Hareuveni, Yael Sharon, Ronit Friling, Lazha Sharief, Sue Lightman, Oren Tomkins-Netzer
PURPOSE: To determine the risk factors for the development of cataract in children with uveitis of any etiology. DESIGN: Cohort study METHODS: 247 eyes of 140 children with uveitis were evaluated for the development of vision affecting cataract. Demographic, clinical and treatment data were collected between the time of presentation and the first instance cataract was recorded or findings at final follow-up. Main outcome measures included prevalence of cataract and distribution by type of uveitis, incidence of new onset cataract time to cataract development and risk factors for the development of cataract...
February 28, 2017: American Journal of Ophthalmology
https://www.readbyqxmd.com/read/28229433/adalimumab-a-review-in-non-infectious-non-anterior-uveitis
#15
Sheridan M Hoy
Adalimumab (Humira(®)) is a tumour necrosis factor (TNF)-α inhibitor available in various countries worldwide, including the USA, Japan and those of the EU, for the treatment of non-infectious intermediate, posterior and panuveitis in adults. It is the first biological agent approved for this indication. In two multinational, phase III studies in adults with active and inactive disease, subcutaneous adalimumab significantly reduced the risk of treatment failure relative to placebo following the tapered withdrawal of corticosteroid therapy...
February 22, 2017: BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
https://www.readbyqxmd.com/read/28188020/efficacy-of-immunomodulatory-therapy-with-interferon-%C3%AE-or-glatiramer-acetate-on-multiple-sclerosis-associated-uveitis
#16
D Velazquez-Villoria, C Macia-Badia, A Segura-García, S Pastor Idoate, G Arcos-Algaba, L Velez-Escola, J García-Arumí
AIM: To analyse the role of interferon-β or glatiramer acetate in reducing the inflammatory episodes of intra-ocular inflammation in multiple sclerosis-associated uveitis. METHOD: A study was conducted on a non-randomised, retrospective case series of 13 patients with proven multiple sclerosis and uveitis (minimum follow-up, 12 months). All patients were given immunomodulatory treatment (interferon-β or glatiramer acetate) to control the course of the multiple sclerosis...
February 7, 2017: Archivos de la Sociedad Española de Oftalmología
https://www.readbyqxmd.com/read/28151857/association-between-intermediate-uveitis-and-toxocariasis-in-the-korean-population
#17
Jin-Woo Kwon, Yoonseob Sim, Donghyun Jee
The aim of the study was to investigate the characteristics of ocular toxocariasis (OT) presenting with intermediate uveitis in the Korean population.We studied intermediate uveitis patients using ocular and systemic evaluations and a Toxocara IgG serology test.Of 50 intermediate uveitis patients, 19 were seropositive for Toxocara IgG. Of the 19 OT patients, 4 presented with recurrence within 6 months and were significantly younger than nonrecurrence patients (P = 0.009). Thirteen patients had a history of eating raw cow liver...
February 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28140700/adalimumab-for-the-treatment-of-uveitis
#18
Kara C LaMattina, Debra A Goldstein
Adalimumab, an inhibitor of tumor necrosis factor-alpha (TNFα), is the only systemic non-corticosteroid agent which has been approved by the US Food and Drug Administration (FDA) for the treatment of non-infectious uveitis. Areas covered:The aim of this review is to summarize the research which demonstrated the effectiveness of adalimumab in the treatment of intraocular inflammation and helped to establish its side effect profile, ultimately leading to its FDA approval. Expert commentary:Adalimumab is a useful second-line agent in the treatment of non-infectious uveitis...
January 31, 2017: Expert Review of Clinical Immunology
https://www.readbyqxmd.com/read/28129017/retinal-capillaritis-in-a-crb1-associated-retinal-dystrophy
#19
Vittoria Murro, Dario Pasquale Mucciolo, Andrea Sodi, Lorenzo Vannozzi, Cinzia De Libero, Gabriele Simonini, Stanislao Rizzo
PURPOSE: To report a case of CRB1-associated retinal dystrophy characterized by vitritis, retinal capillaritis, and cystoid macular edema (CME). METHODS: A case report. RESULTS: An 8-year-old boy was diagnosed with intermediate uveitis and treated with corticosteroids. He was subsequently diagnosed with retinal dystrophy and found to have two CRB1 mutations. CONCLUSIONS: Retinal capillaritis, vitritis, and CME could be inflammatory features of CRB1 retinal dystrophy in our young patient...
January 27, 2017: Ophthalmic Genetics
https://www.readbyqxmd.com/read/28108140/steroid-treatment-in-ocular-tuberculosis-a-double-edged-sword
#20
S Souissi, T David, L Beral
INTRODUCTION: We report the case of a Caribbean patient with an atypical presentation of bilateral tuberculous chorioretinopathy. PATIENT AND METHODS: A 57-year-old woman, with hypertension and non-insulin dependent diabetes, was referred to our center for a sudden loss of vision in the right eye to hand motions. Ophthalmic examination revealed only right papilledema. Brain magnetic resonance imaging was normal. Laboratory examination revealed no signs of inflammation...
February 2017: Journal Français D'ophtalmologie
keyword
keyword
79844
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"